Sign In
Buy MBRX
$0.400
-0.620 (-60.78%)
At Close: Jul 31, 2026
MBRX Stock: Over 10% Pre-Market Explanation
08:07am, Wednesday, 14'th Apr 2021
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) increased by over 10% pre-market. This is why it happened.
Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma
07:35am, Wednesday, 14'th Apr 2021
HOUSTON, April 14, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates tar
MBRX Stock Price Increased Over 20% Pre-Market: Why It Happened
08:14am, Tuesday, 30'th Mar 2021
The stock price of Moleculin Biotech, Inc., (Nasdaq: MBRX) fell by over 20% pre-market. This is why it happened.
Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases
07:30am, Tuesday, 30'th Mar 2021
HOUSTON, March 30, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting
Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020
07:30am, Wednesday, 24'th Mar 2021
HOUSTON, March 24, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin
HOUSTON, Feb. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi
MBRX Stock Price Falls Over 16% Pre-Market: Why It Happened
08:01am, Wednesday, 03'rd Feb 2021
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) fell over 16% pre-market as of 7:55 AM ET today. This is why it happened.
Moleculin Announces Proposed Underwritten Public Offering
04:22pm, Tuesday, 02'nd Feb 2021
HOUSTON, Feb. 2, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin
MBRX Stock Price Increases Over 60% Pre-Market: Why It Happened
09:16am, Tuesday, 02'nd Feb 2021
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) is trading at over 60% pre-market as of 9:12 AM ET. This is why it happened.
Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial
07:30am, Monday, 01'st Feb 2021
HOUSTON, Feb. 1, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi
MBRX Stock Price Increases Over 400% Pre-Market: Why It Happened
07:08am, Monday, 01'st Feb 2021
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) has increased by over 400% pre-market. This is why it happened.
Moleculin Announces Reverse Stock Split
09:15am, Friday, 29'th Jan 2021
HOUSTON, Jan. 29, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin Biotech (MBRX) Jumps: Stock Rises 8.5%
11:17am, Tuesday, 12'th Jan 2021
Moleculin Biotech (MBRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference
07:30am, Thursday, 07'th Jan 2021
HOUSTON, Jan. 7, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi
Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
07:30am, Tuesday, 29'th Dec 2020
HOUSTON, Dec. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
